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CEREBRAL VENOUS THROMBOSIS AND HEPATITIS
Case report
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ABSTRACT - Among the many infective causes of cerebral venous thrombosis (CVT), viral hepatitis is been
re g a rded as a rare associated condition. We re p o rt on a 56-years-old man presenting CVT associated with
hepatitis B and C coinfections outlining probable pathogenic mechanisms. We suggest that virus B and C
serology should be performed in the cases of cerebral venous thrombosis with unknown etiology.
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Trombose venosa cerebral e hepatite: relato de caso
RESUMO - Dentre as várias causas infecciosas de trombose venosa cerebral (TVC), a hepatite viral tem sido
reconhecida como causa rara de TVC. Relatamos sobre um homem de 56 anos com TVC associada a coin-
fecção pelos vírus B e C da hepatite, ressaltando possíveis mecanismos patogênicos. Sugerimos que soro l o-
gia para vírus da hepatite B e C deveria ser solicitado em todos os casos de TVC de origem indeterm i n a d a .
PALAVRAS-CHAVE: trombose venosa cerebral, vírus da hepatite B, vírus da hepatite C.
The main recognized causes or predisposing con-
ditions to cerebral venous thrombosis (CVT) can be
divided into two groups: infectious (either local or
systemic) and non-infectious causes1 - 3. There is also
a third group without specific etiology, which may
c o rrespond to 20% to 35% of the total causes4.
C h ronic hepatitis C virus (HCV) infection has been
c o n s i d e red as a rare cause of cerebral venous thro m-
bosis5-10.
We re p o rt a case of such association and discuss
possible physiopathogenic mechanisms. 
CASE
A 56-year-old white man was admitted to our hospital
with a 15-day history of headache worsening with consid-
erable change in its frequency and intensity patterns. He
was a chronic daily headache suff e rer taking amitry p t i l i n e
75 mg and propranolol 80 mg per day and had already tak-
en several abortive treatment regimens. Four days before
admission he had two episodes of focal motor seizure. His
past history included heavy smoking and drinking. He took
intravenous cocaine for 20 years until 12 years ago. He also
had occasional bisexual relations. General physical exami-
nation was unremarkable. Neurological exam abnorm a l i-
ties included left mild hemiparesis. Pain relief medication
was initiated as well as carbamazepine 600 mg per day.
Routine blood and urine exams were unremarkable. On
c e rebral spinal fluid (CSF) the initial pre s s u re was 33 cm/H2O
with cell count and biochemistry within normal parameters.
Chest radiograph was normal such as cranial comput-
ed tomography scan (CT). Cranial magnetic resonance imag-
ing (MRI) indicated superior sagittal and left transverse
sinuses thrombosis associated to corpus callosum and right
parietal hemorrhagic venous infarcts. New blood sample
was taken in order to investigate possible secondary eti-
ologies and on that time venous non-fractionated heparin
was initiated.
Values of serum immunoglobulins were: IgA=151 mg/dL
(78-367 mg/dL), IgG=703 mg/dL (583-1761 mg/dL) and IgM=
69 mg/dL (52-335 mg/dL). The following autoantibodies were
negative: antinuclear, anti-ds-DNA, anti-Sm, rh e u m a t h o i d
f a c t o r, anti-Scl-70, RNP, anti-SS-A/Ro, anti-SS-B/la, IgM and
IgG anticardiolipins and ANCA. Serum complement values
w e re: CH50=219 UI/mL (Normal value, NV=130-330 UI/mL)
and C2=100% (NV >70%). Cryoglobulins were also negative.
Results from blood serology were as follow: VDRL neg-
ative; anti-HCV positive (enzyme immunoassay); HBsAg neg-
ative, anti-HBc positive and anti-HBs positive (prior hepa-
titis B virus infection); Chagas’ disease negative; HTLV- I / I I
negative and HIV negative. Chronic HCV infection was con-
f i rmed through serum HCV RNA detection by PCR tech-
nique. Thrombophilic states were sought but antithro m-
bin III, factor V Leiden and protein C and S levels were with-
in normal limits.
Anticoagulation was maintained with warfarin for six
months and then suspended. Hepatological follow-up was
initiated but the patient refused liver biopsy. He is still re f e r-
ring headache but less frequently and less intense and takes
phenobarbital 100 mg per day. General and neuro l o g i c a l
exams are unremarkable.
The patient signed informed consent allowing his per-
sonal data publication.
DISCUSSION
T h e re is considerable evidence that pro t h ro m b o t-
ic states may develop soon after atero t h rombotic or
c a rdioembolic cerebral infarct. Cerebral venous thro m-
bosis, on the other hand, is usually a consequence of
these procoagulant conditions11-13.
Tough re p o rted mechanisms of cerebral venous
t h rombosis in patients with hepatitis B and C are not
fully understood, there is growing evidence that these
v i ruses alone or in combination with a series of oth-
er factors may shift the delicate pro c o a g u l a n t / t h ro m-
bolysis balance toward thrombosis10.
It is known that hepatitis C virus (HCV) infection
may be associated with anticardiolipin antibodies.
Thus, HCV might lead to thrombotic complications
and should be considered as one of the antiphospho-
lipid syndrome possible causes6 , 7. In the present case,
a n t i c a rdiolipin antibodies were negative as well as
other autoantibodies.
Subjects with chronic hepatitis C who are receiv-
ing interf e ron-alpha (INF-alpha) have an incre a s e d
risk of diabetes mellitus and hypert r i g l i c e r i d e m i a1 4 , 1 5.
T h e re f o re, INF-alpha can be considered as a risk fac-
tor for hypercoagulable states. In addition, either
INF-alpha or HCV have been re p o rted to induce a
variety of antibodies, not only anticardiolipin but
also cryoglobulins, rheumatoid factor, antinuclear,
antismooth muscle, anti-LKM and antithyre o g l o b u-
l i n5 , 1 6. Since the diagnosis of hepatitis came while in-
vestigation was carried out our patient was not re-
ceiving INF-alpha or any other medication that could
increase thrombosis risk.
In spite of the possible relationship between HCV
and antiphospholipid syndrome, other data suggest
that HCV, per se, might be responsible for thro m b o t-
ic events8. It is speculated that the HCV envelope pro-
tein has a procoagulant activity and that the viru s
genome encodes serine proteases that could also act
as procoagulant17.
In this case, the possibility of a pathogenic role of
occult hepatitis B virus (HBV) infection can not be ful-
ly discarded, since molecular tests for HBV DNA detec-
tion have not been done1 8. Nonetheless, we could
find only one re p o rt of cerebral venous thro m b o s i s
associated to hepatitis B (HBV). That was the case of
a 43-year-old male who presented with seizures and
had a previous history of HBV. He developed a left
transversal sinus thrombosis associated to left tem-
poral posterior hemorrhagic infarct. On investiga-
tion, anticardiolipin antibodies were negative tough
t h e rewas an antithrombin III and protein C deficien-
c y9. In the present case, there was also the associa-
tion between sinus thrombosis and hemorrh a g i c
venous infarct. However, antithrombin and pro t e i n
C levels were normal.
To conclude, since our patient was not taking INF-
alpha and any identifiable procoagulant cause was
recognized, the hypothesis of HCV (and maybe HBV)
as thrombogenic agent deserves further attention.
We also suggest that HCV and HBV tests should be
routinely included in the investigation of cere b r a l
venous thrombosis of unknown etiology.
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